article thumbnail

LimFlow Limits Limb-Threatening Ischemia

CardiacWire

Late-breaking second year results from the PROMISE II trial showed that the LimFlow system achieved strong outcomes for avoiding amputations and promoting limb salvage among “no-option” patients with chronic limb-threatening ischemia (CLTI). Ischemia in the treated limb also decreased significantly, with 65.8%

article thumbnail

Cleerly Launches Cleerly ISCHEMIA Solution for Heart Disease Analysis

DAIC

milla1cf Tue, 01/09/2024 - 11:32 January 9, 2024 — Cleerly , the company working to create a new standard of care for the diagnosis of heart disease, announced the launch of Cleerly ISCHEMIA , which recently received U.S. Cleerly ISCHEMIA is a transformative addition poised to reshape the landscape of cardiac care.”

Ischemia 119
article thumbnail

Revascularization Strategies in Stable Coronary Artery Disease: ISCHEMIA Trial Insights

Cardiology Update

In the ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trial, researchers examined the risk of ischemic events in patients with stable coronary artery disease. For more cardiology research news join our newsletter or follow us on Twitter , Facebook , LinkedIn or Instagram.

article thumbnail

Decoding the Menace Within: Unraveling Myocardial Bridges and Exercise-Induced Ischemia

Cardiology Update

As the medical community delves deeper into the intricacies of ANOCA, the study provides a compelling narrative for clinicians and researchers alike, aiming to decipher the complexities of myocardial bridges and their role in exercise-induced ischemia. Original article: Sinha A et al. Original article: Sinha A et al.

Exercise 119
article thumbnail

Researchers prevent myocardial ischemia/reperfusion injury with oral fullerenes

Medical Xpress - Cardiology

However, reperfusion itself could induce more severe injury, called myocardial ischemia/reperfusion injury (MI/RI). The most effective treatment for MI in clinic is reperfusion, e.g., interventional or thrombolytic therapy.

article thumbnail

Cleerly ISCHEMIA Software Device Billable With AMA Category I CPT Code for Noninvasive Estimates of Fractional Flow Reserve

DAIC

Food and Drug Administration ( FDA )-cleared Cleerly ISCHEMIA software device applied to a non-invasive coronary CT angiogram ( CCTA ) can be billed using the new Category I CPT code 75580. Prior studies have demonstrated the independent and incremental benefit of Cleerly ISCHEMIA applied to CCTA beyond traditional assessment.

Ischemia 105
article thumbnail

BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

DAIC

a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the primary endpoint results of the open label roll-in cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial. Getty Images milla1cf Thu, 05/02/2024 - 10:12 May 2, 2024 — BioCardia, Inc. ,